Development of a Quality of Life Decision-Making Model for Older Patients with Acute Myeloid Leukemia

老年急性髓系白血病患者生活质量决策模型的开发

• 批准号: 10155586
• 负责人: Sara Tinsley
• 金额: $ 15.79万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-04 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10155586
• 关键词: Acute Myelocytic Leukemia; Address; Adult Acute Myeloblastic Leukemia; Affect; Aftercare; Age; Age-Years; Bone Marrow; Cancer Center; Cancer Survivor; Caregivers; Caring; Characteristics; Clinical; Clinical Research; Cytogenetics; Decision Making; Dependence; Development; Diagnosis; Disease; Family; Future; Goals; Individual; K-Series Research Career Programs; Knowledge; Learning; Life; Malignant Bone Neoplasm; Measurement; Measures; Modeling; Monitor; National Institute of Nursing Research; Newly Diagnosed; Nurses; Outcome; PF4 Gene; Palliative Care; Patient Preferences; Patients; Pilot Projects; Population; Predictive Factor; Probability; Process; Publications; Quality of life; Randomized Controlled Trials; Research; Research Design; Research Personnel; Risk; Site; Statistical Methods; Strategic Planning; Supportive care; Survival Rate; Symptoms; Testing; Therapeutic; Transfusion; United States National Institutes of Health; Work; aged; associated symptom; base; burden of illness; career; chemotherapy; common symptom; comorbidity; data management; design; end of life care; functional status; high risk; improved; individual patient; innovation; older patient; optimal treatments; patient population; physical symptom; preference; routine care; skills; symptomatic improvement; treatment as usual; treatment choice; trial comparing

Project Summary/Abstract Older patients (≥ 60 years of age) with acute myeloid leukemia (AML) do not have enough information, based on research, to determine the best chemotherapy treatment that aligns with their goals, whether for survival or improved quality of life (QOL). This proposal seeks to identify significant patient factors and disease characteristics in order to build a patient decision-making model focused on QOL, while monitoring survival. This will provide an aid to patients when choosing the most appropriate treatment that optimally aligns with their goals for care. This career development award constructs a patient QOL decision-making model integrating significant clinical disease and patient factor predictors in older patients diagnosed with AML at Moffitt Cancer Center. The Specific Aims of the research are to: 1) Describe differences in QOL among newly diagnosed older AML patients receiving intensive versus non-intensive chemotherapy (at baseline and 30, 60, 90 and 180 days post treatment); 2) Identify the individual clinical disease characteristics (blast percentage, transfusion dependence, and cytogenetic risk group), and patient factors (age, comorbidities, functional status, and physical symptoms) of newly diagnosed older AML patients that predict their QOL among those receiving two treatments, intensive versus non-intensive chemotherapy; 3) Design a patient decision making model integrating significant clinical disease and patient factor predictors of QOL for newly diagnosed older AML patients receiving intensive versus non-intensive treatment. Probability will be provided to patients in pie charts for survival and total QOL score with treatment intensity. Proposed Career and Learning Objectives are to: 1) Develop expertise in palliative care, focused on the unique needs of individuals diagnosed with acute myeloid leukemia; 2) Attain skills and knowledge for the clinical research application of decision-making model research; 3) Attain advanced skills in study design, data management, measurement, and statistical methods to identify factors; 4) Disseminate findings through publications and presentations; 5) Develop grantsmanship skills. Long-term career goal: Randomized controlled trial comparing the alignment of treatment with preferences in older patients with AML with integration of the model into their care to usual care.

项目摘要/摘要 患有急性髓样白血病（AML）的老年患者（≥60岁）没有足够的信息， 基于研究，确定与目标保持一致的最佳化学疗法治疗 生存或改善生活质量（QOL）。该建议旨在确定重要的患者因素和 疾病特征是为了建立一个以QOL为本的患者决策模型，同时进行监测 生存。这将为患者提供最佳对齐的最合适的治疗时的帮助 他们的护理目标。 该职业发展奖构建了患者QOL决策模型，集成了重要的临床 莫菲特癌症中心诊断为AML的老年患者的疾病和患者因素预测因子。这 该研究的具体目的是：1）描述新诊断的旧AML之间QOL的差异 接受密集型与非密集化疗的患者（基线和30、60、90和180天 治疗后）； 2）确定个体临床疾病特征（爆炸百分比，输血 依赖性和细胞遗传风险组）以及患者因素（年龄，合并症，功能状态和 新诊断的老年AML患者的身体症状）在接受两个人中预测其QOL 治疗，强化与非密集型化学疗法； 3）设计患者决策模型 将重大临床疾病和患者因子预测因素整合到新诊断的老年AML的QOL预测因子 接受密集与非密集型治疗的患者。 PIE的患者将提供概率 生存的图表和QOL总评分均具有治疗强度。 拟议的职业和学习目标是：1）在姑息治疗方面发展专业知识，专注于 诊断患有急性髓性白血病的人的独特需求； 2）获得技能和知识 决策模型研究的临床研究应用； 3）获得研究设计的高级技能，数据 识别因素的管理，测量和统计方法； 4）通过 出版物和演示； 5）发展授予技巧。 长期职业目标：随机对照试验比较治疗的对准与偏好的比较 具有AML的老年患者，并将模型整合到他们的护理中。